- Home
- LEGT vs TNGX Comparison
LEGT vs TNGX Comparison
Compare LEGT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGT
- TNGX
- Stock Information
- Founded
- LEGT 2023
- TNGX 2014
- Country
- LEGT United States
- TNGX United States
- Employees
- LEGT N/A
- TNGX N/A
- Industry
- LEGT
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- LEGT
- TNGX Health Care
- Exchange
- LEGT Nasdaq
- TNGX Nasdaq
- Market Cap
- LEGT 268.6M
- TNGX 317.4M
- IPO Year
- LEGT 2024
- TNGX N/A
- Fundamental
- Price
- LEGT $10.38
- TNGX $2.36
- Analyst Decision
- LEGT
- TNGX Strong Buy
- Analyst Count
- LEGT 0
- TNGX 8
- Target Price
- LEGT N/A
- TNGX $13.14
- AVG Volume (30 Days)
- LEGT 18.5K
- TNGX 574.3K
- Earning Date
- LEGT 01-01-0001
- TNGX 03-17-2025
- Dividend Yield
- LEGT N/A
- TNGX N/A
- EPS Growth
- LEGT N/A
- TNGX N/A
- EPS
- LEGT 0.32
- TNGX N/A
- Revenue
- LEGT N/A
- TNGX $43,383,000.00
- Revenue This Year
- LEGT N/A
- TNGX $27.73
- Revenue Next Year
- LEGT N/A
- TNGX N/A
- P/E Ratio
- LEGT $0.66
- TNGX N/A
- Revenue Growth
- LEGT N/A
- TNGX 15.67
- 52 Week Low
- LEGT $10.00
- TNGX $2.35
- 52 Week High
- LEGT $10.47
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- LEGT N/A
- TNGX 33.13
- Support Level
- LEGT N/A
- TNGX $2.35
- Resistance Level
- LEGT N/A
- TNGX $2.51
- Average True Range (ATR)
- LEGT 0.00
- TNGX 0.22
- MACD
- LEGT 0.00
- TNGX -0.04
- Stochastic Oscillator
- LEGT 0.00
- TNGX 0.94
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.